Stock Report

AstraZeneca Pharma India Ltd Q1FY22 PAT at Rs. 10.24 crore



Posted On : 2021-08-09 14:24:58( TIMEZONE : IST )

AstraZeneca Pharma India Ltd Q1FY22 PAT at Rs. 10.24 crore

AstraZeneca Pharma India Ltd. has reported financial results for the period ended June 30, 2021.

Financial Results (Q1 FY 2021-22) - QoQ Comparison

The company has reported total income of Rs.178.30 crores during the period ended June 30, 2021 as compared to Rs.212.80 crores during the period ended March 31, 2021.

The company has posted net profit / (loss) of Rs.10.24 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.27.27 crores for the period ended March 31, 2021.

The company has reported EPS of Rs.4.10 for the period ended June 30, 2021 as compared to Rs.10.91 for the period ended March 31, 2021.

FinancialsQ1 FY2021-22Q4 FY20-21% Change
Total Income₹ 178.30 crs₹ 212.80 crsDown Tick -16.21%
Net Profit₹ 10.24 crs₹ 27.27 crsDown Tick -62.45%
EPS₹ 4.10₹ 10.91Down Tick -62.42%

Financial Results (Q1 FY 2021-22) - YoY Comparison

The company has reported total income of Rs.178.30 crores during the period ended June 30, 2021 as compared to Rs.196.22 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.10.24 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.18.83 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.4.10 for the period ended June 30, 2021 as compared to Rs.7.46 for the period ended June 30, 2020.

FinancialsQ1 FY2021-22Q1 FY2020-21% Change
Total Income₹ 178.30 crs₹ 196.22 crsDown Tick -9.13%
Net Profit₹ 10.24 crs₹ 18.83 crsDown Tick -45.62%
EPS₹ 4.10₹ 7.46Down Tick -45.04%

Shares of AstraZeneca Pharma India Ltd. was last trading in BSE at Rs. 3410.75 as compared to the previous close of Rs. 3461.2. The total number of shares traded during the day was 2152 in over 656 trades.

The stock hit an intraday high of Rs. 3498 and intraday low of 3401. The net turnover during the day was Rs. 7411798.

Source : Equity Bulls

Keywords